Bilirubin as a metabolic hormone: the physiological relevance of low levels.
Creeden JF, Gordon DM, Stec DE, Hinds TD Jr.
Am J Physiol Endocrinol Metab. 2021 Feb 1;320(2):E191-E207. doi: 10.1152/ajpendo.00405.2020. Epub 2020 Dec 7.
Bilirubin in clinical practice: a review.
Fevery J.
Liver Int. 2008 May;28(5):592-605. doi: 10.1111/j.1478-3231.2008.01716.x.
Neonatal hyperbilirubinemia and the role of unbound bilirubin.
Hegyi T, Kleinfeld A.
J Matern Fetal Neonatal Med. 2022 Dec;35(25):9201-9207. doi: 10.1080/14767058.2021.2021177. Epub 2021 Dec 26.
[BILIRUBIN--PHYSIOPATHOLOGY].
DEGROOTE J.
Tijdschr Gastroenterol. 1964;7:254-69.
[Bilirubin metabolism].
Magnenat P.
Rev Med Suisse Romande. 1970 Oct;90(10):801-10.
Bilirubin, a hepatoprotective agent that activates SIRT1, PGC-1alpha, and PPAR-alpha, while inhibiting NF-kappaB in rats with metabolic-associated fatty liver disease.
Taghizadeh M, Maleki MH, Vakili O, Tavakoli R, Zarei P, Dehghanian A, Bordbar H, Shafiee SM.
Sci Rep. 2024 Nov 25;14(1):29244. doi: 10.1038/s41598-024-80119-5.
Association of bilirubin with neurodegenerative disorders: A prospective cohort study from UK biobank.
Wang Y, Bai Y, Li C, Chen K, Shang H.
Parkinsonism Relat Disord. 2025 Sep;138:107973. doi: 10.1016/j.parkreldis.2025.107973. Epub 2025 Jul 28.
[Bilirubin].
Robert JF.
Infirm Fr. 1974 Nov;(159):17-20, 22.
[Bilirubin].
VINK CL.
Maandschr Kindergeneeskd. 1954 Oct;22(10):334-45.
Bilirubin: A Promising Therapy for Parkinson's Disease.
Jayanti S, Moretti R, Tiribelli C, Gazzin S.
Int J Mol Sci. 2021 Jun 9;22(12):6223. doi: 10.3390/ijms22126223.
